Therapy Areas-Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

EN 

About Us
About Us
Overview

History

Honor

Leadership

Contact Us
Continuous innovation for better Life

Hansoh Pharma, a leading innovation-driven pharmaceutical company in the PRC, is committed to improving human health through unremitting innovation, focusing mainly on such areas as anti-tumor, anti-infectives, CNS diseases, metabolic diseases, autoimmune diseases.
Innovation
Innovation
Achievements

Therapy Areas

R&D Platforms

R&D Capability

Business Development

Manufacturing

Quality Management
Continuous innovation for better Life

Hansoh Pharma, a leading innovation-driven pharmaceutical company in the PRC, is committed to improving human health through unremitting innovation, focusing mainly on such areas as anti-tumor, anti-infectives, CNS diseases, metabolic diseases, autoimmune diseases.
Products
Products
Our Products

Market Coverage
Continuous innovation for better Life

After more than 20 years of continuous investment in R&D, Hansoh Pharma has marketed 6 innovative drugs and has over 30 innovative drug programs in different clinical stages with over 40 clinical trials in progress, forming a rich pipeline.
News
News
Press Releases

Media Center
Hansoh Pharma Updates

Find the latest and most complete information about Hansoh Pharma!
Investors
Investors
Company Information

Corporate Governance

Financial Information

Announcements and Circulars

Investor Contact
Continuous innovation for better Life

Hansoh Pharma, a leading innovation-driven pharmaceutical company in the PRC, is committed to improving human health through unremitting innovation, focusing mainly on such areas as anti-tumor, anti-infectives, CNS diseases, metabolic diseases, autoimmune diseases.
ESG
ESG
ESG Management

ESG Practice and Honor

ESG Reports
Responsibility integrity diligence innovation

Hansoh Pharma has always focused on corporate governance, corporate behavior, product safety and quality, access to healthcare, human resource development, environmental protection and community enhancement as the focus and the basis of ESG management, and has been continually committed to improving the medicine availability and the innovative development in fields with unmet clinical needs.
Careers
Careers
Work with Us

Join Us
Work with us

We welcome talents worldwide to join us with their entrepreneurship and achieve new levels of success in their career!

About Us 
- Back
- Overview
- History
- Honor
- Leadership
- Contact Us
Innovation 
- Back
- Achievements
- Therapy Areas
- R&D Platforms
- R&D Capability
- Business Development
- Manufacturing
- Quality Management
Products 
- Back
- Our Products
- Market Coverage
News 
- Back
- Press Releases
- Media Center
Investors 
ESG 
- Back
- ESG Management
- ESG Practice and Honor
- ESG Reports
Careers 
- Back
- Work with Us
- Join Us



Related Links

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Therapy Areas

Home > Innovation > Therapy Areas

Achievements Therapy Areas R&D Platforms R&D Capability Business Development Manufacturing Quality Management

Therapy areas

Our company focuses on the research and development of new drugs in the therapeutic areas of oncology, anti-infectives, CNS diseases, metabolic diseases and autoimmune diseases. It has established a comprehensive innovative R&D platform and is currently conducting 40+ clinical trials of innovative drugs from 30+ innovative drug projects in various clinical stages.

Anti-tumor

We focus on the develoment of new drugs in the field of common and hostile cancers.Our innovative medicine programs in clinical trials include HS-20106injections、HS-20105、HS-20117、HS-10516 capsules、HS-10382 tablets、HS-10370 tablets、HS-10386 tablets、HS-10502 tablets、HS-10365 capsules、HS-20089 /HS-20093 、HS-10375 tablets、HS-10381 capsules etc.Our product portfolio mainly includes the innovative drug Ameile (aumolertinib mesylate tablets), the innovative drug Hansoh Xinfu (flumatinib mesylate tablets), Pulaile (pemetrexed disodium for injection), Xintai (bortezomib for injection) ,Xinwei (imatinib mesylate tablets) and Tanneng (fosaprepitant dimeglumine for injection).
Anti-infectives

We focus on the development of new drugs in the fields of antiviral, anti-complex bacterial infection and anti-fungal infection. Our innovative medicine programs in clinical trials include HS-10366 tablets etc.Our product portfolio mainly includes the innovative drug Hengmu (tenofovir amibufenamide tablets), the innovative drug Mailingda (morinidazole sodium chloride injection), Zetan (tigecycline for injection) and Hengsen (micafungin sodium for injection).
CNS Diseases

We focus on the development of new drugs in the fields of psychiatric and neurological disorders.Our innovative medicine programs in clinical trials include HS-10380 tablets、HS-10506 tablets，etc. Our product portfolio mainly includes the innovative drug Xinyue (inebilizumab injections, anti-CD19 mAb), Oulanning (olanzapine oral dose formulations), Ailanning (paliperidone extended-release tablets) and Ameining (agomelatine tablets).
Metabolic and others

We focus on the development of new drugs in the field of metabolic diseases such as diabetes and obesity. Our innovative medicine programs in clinical trials include HS-10511 tablets、HS-20094 injections、HS-10384 tablets、HS-10518 capsules etc.Our product portfolio mainly includes the innovative drug Fulaimei (PEG-loxenatide for injection), Fulaidi (repaglinide tablets) and Fulairui (canagliflozin tablets).
Autoimmune Diseases

We focus on the development of new drugs in the field of autoimmune diseases. Our innovative medicine programs in clinical trials includeHS-10374 tablets etc.